Related Experiment Videos

[The binding characteristics of insulin-MTX to insulin receptor]

X Ou1, A Kuang, Z Liang

  • 1Department of Nuclear Medicine, First Affiliated, Hospital WCUMS, Chengdu 610041, China.

Hua Xi Yi Ke Da Xue Xue Bao = Journal of West China University of Medical Sciences = Huaxi Yike Daxue Xuebao
|January 17, 2003
PubMed
Abstract

Insights

Researchers developed insulin-methotrexate (MTX) to target cancer cells. This conjugate binds to insulin receptors on tumors, showing potential for targeted drug delivery in carcinoma therapy.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Context:

  • Tumors often overexpress insulin receptors.
  • Insulin can be internalized by cells and potentially reach the nucleus.
  • This presents an opportunity for targeted drug delivery.

Purpose:

  • To investigate the receptor binding characteristics of insulin-methotrexate (MTX).
  • To assess the potential of using insulin as a carrier for receptor-mediated carcinoma targeted therapy.

Summary:

  • Insulin was covalently linked to methotrexate (MTX) to create an insulin-MTX conjugate.
  • The binding affinity of insulin-MTX to insulin receptors was evaluated using competitive displacement assays.
  • Insulin-MTX demonstrated effective competition with 125I-insulin for insulin receptor binding.

Impact:

  • Insulin-MTX exhibits high-affinity binding to insulin receptors.
  • This finding supports the potential of insulin as a carrier for targeted cancer therapy.
  • Further research may lead to novel strategies for treating hepatocellular carcinoma.

Related Concept Videos